US statin eligibility rises to 56.6% in 2026 rules

Updated 2026 cardiovascular guidelines have expanded the number of U.S. adults advised to consider statin therapy, with eligibility rising to about 56.6% of people ages 30 to 79, officials involved in the update said. They said this equates to roughly 87.5 million individuals who now meet the recommended thresholds for cholesterol-lowering medication.

Officials said the revised guidance would bring an estimated 21.5 million additional people into recommended consideration compared with the 2018 standards, reflecting a broader prevention approach in routine care. They also stressed that expanded recommendations come alongside existing gaps in treatment and follow-up for patients already considered at elevated risk.

How the 2026 guidance expands who is advised to consider statins Officials linked the higher eligibility rate to two design changes in how cardiovascular risk is assessed and translated into action. One change is the use of a longer horizon in risk modeling, including 30-year projections. The other is an adjustment in treatment thresholds, which the update describes as lower than before. Officials said the combined effect of longer-term modeling and lower thresholds can move more adults into prevention discussions. Those conversations may include whether to begin medication and the monitoring that typically accompanies ongoing therapy and risk management. Why a 30-year risk horizon is emphasized for younger adults The guidance frames the longer time window as especially relevant for younger adults. Officials said these patients can appear to have a lower likelihood of near-term events while still accumulating meaningful exposure to risk factors over time. By incorporating 30-year projections By incorporating 30-year projections, officials said the intent is to identify risk earlier and allow prevention planning over a longer period, rather than relying solely on short-term event estimates when determining next steps.

LDL targets, treatment gaps, and capacity strain Data cited alongside the updated recommendations points to shortfalls in achieving the newer, more stringent LDL cholesterol targets. More than 80% of people with established heart disease are not reaching those LDL targets, the data shows.

The update also highlights access and continuity barriers among patients described as high risk. More than one-third of high-risk patients are described as lacking access to, or not receiving, prescribed cholesterol-lowering therapies, officials said, underscoring uneven baseline treatment rates and outcomes.

Officials said the broader eligibility picture implies added demand for preventive cardiovascular services, including risk evaluation, starting therapy when appropriate, and maintaining follow-up over time. The update also indicates that some existing patients may be guided toward lower LDL goals, adding to ongoing monitoring needs in clinical settings.

PREVENT risk tool changes how patients are categorized

A key operational shift in the 2026 update is the move to the PREVENT risk assessment tool, the guidance says. Data indicates PREVENT reclassifies about 21.5% of the adult population into different risk categories, changing who is labeled low, intermediate, or high risk in clinical workflows.

The guidance describes the overall share recommended for therapy as broadly stable at the population level, while noting that the new tool shifts risk profiles based on gender, diabetes status, and ethnicity. The update says clinicians and health systems will need to adjust workflows to reflect the new categorization and support individualized decisions, including greater use of diagnostic imaging to help guide choices when estimates change.